



Current Agreements

Dealdoc

Manufacturing agreement for diabetes, cardiovascular and oncology products

Sanofi

Awamedica

Mar 10 2014

Manufacturing agreement for diabetes, cardiovascular and oncology products

Companies:	Sanofi Awamedica
Announcement date:	Mar 10 2014
Deal value, US\$m:	n/d

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Mar 10 2014
Industry sectors:	Bigpharma Pharmaceutical
Brand name:	Daonil, Amaryl, Metformin, Plavix, Tritace, Taxotere and Eloxatin
Asset type:	Product Cardiovascular
Therapy areas:	Metabolic » Diabetes Oncology
Technology types:	Small molecules
Deal components:	Manufacturing
Stages of development:	Marketed

Financials

Deal value, US\$m:	n/d
---------------------------	-----

Termsheet

Sanofi signed a manufacturing agreement for seven key products with Awamedica.

Products cover three key therapeutic areas – diabetes, cardiovascular and oncology.

Awamedica is the first pharmaceutical company based in Erbil developing, manufacturing and marketing products adapted to the needs of the Iraqi market.

The manufacturing agreement follows the international standards for Good Manufacturing Practice and other quality criteria.

The agreement includes seven products from Sanofi portfolio: Daonil, Amaryl, Metformin, Plavix, Tritace, Taxotere and Eloxatin.

Press Release

Sanofi (France) (SAN.PA) And Awamedica Sign A Partnership Agreement For The Manufacturing Of Sanofi Products In Iraq

Erbil, Kurdistan, Iraq, March 10, 2014. Sanofi, a global healthcare leader, today signed a manufacturing agreement for seven key products with Awamedica. Products cover three key therapeutic areas – diabetes, cardiovascular and oncology. Awamedica is the first pharmaceutical company based in Erbil developing, manufacturing and marketing products adapted to the needs of the Iraqi market.

The Kurdistan Regional Government Prime Minister, H.E. Mr. Nechirvan Barzani stated at the signing ceremony: "This partnership brings new opportunities, integrating Sanofi's important medicines and successful marketing model with Awamedica's expertise and quality in

manufacturing, which will encourage growth for both parties and the country. I am pleased to welcome this type of partnership which will positively impact our health care sector."

The KRG Minister of Health, H.E. Dr. Rekawt Rasheed, said: "The Ministry of Health is focused on improving the healthcare services to international standards and to provide high quality services for our people. We encourage collaboration between international and local companies as this will benefit the local market by enhancing healthcare services and improving medical products produced within the country".

Dr. Pius Hornstein, the Vice President of Sanofi for Turkey and Middle East said, "This partnership reaffirms Sanofi's commitment to Iraqi patients, government authorities and health-care system. Sanofi's distributor business model and Awamedica's manufacturing practices is a winning combination. In the first phase of this partnership, Awamedica will begin with packaging our products and then gradually move into the complete production of these products. This will allow for a more efficient transfer of knowledge, while maintaining highest quality standards. Sanofi is committed to working alongside Awamedica to provide a winning model of healthcare to Iraqi patients."

Also commenting on the partnership Dr. Bahram Resul, General Manager and CEO of Awamedica, said: "The signing of this agreement with Sanofi, one of the leading research based pharmaceuticals companies in the world, is recognition of our commitment to quality in all our activities. Our company was founded only a few years ago and from day one quality came first. We look forward to working with Sanofi and step by step widen our cooperation."

Ahmed Ismail, General Manager for Sanofi in Iraq added, "Sanofi is committed to serving the needs of patients, from the moment a molecule is created to the moment the medication is received by a patient. Throughout this process, we will work with Awamedica to enhance the practice of medicine, support the development of the industry, and most of all protect the interests of patients, who are, and will always remain, at the center of all what we do."

The manufacturing agreement follows the international standards for Good Manufacturing Practice and other quality criteria. The agreement includes seven products from Sanofi portfolio: Daonil®, Amaryl®, Metformin, Plavix®, Tritace®, Taxotere® and Eloxatin®.

About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About Awamedica

Awamedica is a privately held pharmaceuticals development, manufacturing and marketing company, with Swedish expertise and quality, based in Erbil, Iraq. With close to one hundred products and two hundred employees the company serves the needs of the Iraqi market within the therapeutic fields of gastroenterology, dermatology, cardiovascular and pulmonary diseases, infections, diabetes, allergy and pain.

Filing Data

Not available.

Contract

Not available.